---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-009567"
form_type: "8-K"
ticker: "PLX"
cik: "0001006281"
company_name: "Protalix BioTherapeutics, Inc."
filed_at: "2024-06-28T23:59:59+00:00"
generated_at: "2026-06-01T00:23:15.103683+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Stockholders approve increase in share reserve for 2006 Stock Incentive Plan to 17.5M shares

## Summary
- Seven directors elected; CEO Dror Bashan among those with over 22M for votes.
- Advisory vote on executive compensation passed: 17.0M for, 9.88M against.
- Stock plan amended: shares available increased from ~12.5M to 17,475,171.
- Kesselman & Kesselman (PwC Israel) ratified as auditor for fiscal 2024.

## SEC filing metadata
- accession: 0001558370-24-009567
- form_type: 8-K
- ticker: PLX
- cik: 0001006281
- company_name: Protalix BioTherapeutics, Inc.
- filed_at: 2024-06-28T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1006281/000155837024009567/0001558370-24-009567-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1006281/000155837024009567/plx-20240627x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-009567
- JSON: https://secwatch.observer/filing/0001558370-24-009567.json
- Plain text: https://secwatch.observer/filing/0001558370-24-009567.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.